J B CHEMICALS AND PHARMA

Develops, manufactures, and sells branded pharmaceutical formulations in India and international markets, with a contract development and manufacturing (CDMO) arm serving major global OTC customers. The India branded formulations business is the largest stream at ₹2,461 cr in FY26 (branded formulations grew 11%), focused on chronic therapies where the business grew 19% against IPM growth of 14%. International formulations generated ₹1,154 cr in FY26 across 40+ countries, while the CDMO segment earned ₹445 cr. The company manufactures oral solids (58% of BRSR turnover mix), injectables, liquids, and medicated lozenges, and is among the top five global manufacturers of medicated lozenges. It runs 8 manufacturing plants in India, serves 28 states domestically plus 40+ countries, and exports contribute 35% of total turnover. Major cost items are materials at ₹912.44 cr (22% of revenue), employee costs at ₹772.7 cr (18.6%), and other operating expenses at ₹971.39 cr (23.4%). In January 2026, Torrent Pharmaceuticals acquired a controlling stake and the company was amalgamated into Torrent effective 8 July 2026, with JB Chemicals dissolved without being wound up.